98%
921
2 minutes
20
Objectives: To systematically compare the predictive accuracy of the Phoenix Sepsis Score (PSS), the Pediatric Sequential Organ Failure Assessment (pSOFA), and systemic inflammatory response syndrome (SIRS) in assessing in-hospital mortality risk among pediatric sepsis patients in non-ICU wards, thereby providing evidence-based support for clinical risk stratification.
Design: This study employed a multicenter retrospective cohort design, enrolling non-ICU pediatric patients with suspected infections (excluding preterm infants and neonates hospitalized immediately after birth), to construct an overall cohort and a neonatal subgroup cohort. Clinical parameters were collected through a data acquisition system, with parallel calculations of PSS, pSOFA, and SIRS scores. The primary endpoint was in-hospital mortality. Receiver operating characteristic (ROC) curves were constructed via R language version 4.3.1, and the discriminatory performance of each scoring system was evaluated via the area under the ROC curve (AUROC).
Results: From January 2023 to September 2024, 965 non-ICU pediatric patients with infections were enrolled from 13 medical centers (overall cohort mortality: 1.1%, 11/965; neonatal subgroup: 193 cases, mortality: 4.1%, 8/193). In the overall cohort, all 11 patients experienced deterioration on the ward and were subsequently transferred to the PICU in accordance with each hospital's protocol; eight of them died from sepsis, and three from septic shock. After multivariate adjustment, the AUROC value of the PSS score in the overall cohort was 0.756 (99% CI: 0.731-0.780), representing a 3.6% improvement over the SIRS criteria (0.730, 99% CI: 0.543-0.873) but lower than the pSOFA score (0.845, 99% CI: 0.568-0.966). In the neonatal subgroup, the AUROC value of the PSS score was 0.764 (99% CI: 0.478-0.927), comparable to that of the SIRS criteria (0.757, 99% CI: 0.475-0.905) but still lower than that of the pSOFA score (0.819, 99% CI: 0.533-0.983). No statistically significant differences were observed among the three scoring systems (P > 0.05).
Conclusions: These findings suggest that the PSS score does not demonstrate superior predictive value compared with traditional assessment tools in non-ICU clinical scenarios.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijid.2025.108044 | DOI Listing |
Hypertension
September 2025
Department of Hypertension, Center for Epidemiological Studies and Clinical Trials, the Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, China (J.W.).
Background: The association between season of screening blood pressure (BP) measurement and adverse outcomes has not been examined among populations without prior physician-diagnosed hypertension. We aimed to investigate the association between the season of screening clinic BP measurement and the risk of all-cause mortality.
Methods: This was a prospective cohort study, and data were analyzed from an ongoing community hypertension screening program in Shanghai between 2018 and 2024.
Stroke
September 2025
Department of Neurology, Yale School of Medicine, New Haven, CT (L.H.S.).
Preclinical stroke research faces a critical translational gap, with animal studies failing to reliably predict clinical efficacy. To address this, the field is moving toward rigorous, multicenter preclinical randomized controlled trials (mpRCTs) that mimic phase 3 clinical trials in several key components. This collective statement, derived from experts involved in mpRCTs, outlines considerations for designing and executing such trials.
View Article and Find Full Text PDFCirc Cardiovasc Interv
September 2025
Keele Cardiovascular Research Group, Keele University, United Kingdom (M.A.M., R.B.).
Background: Evidence informing clinical guidelines assumes that all transcatheter aortic valve implantation (TAVI) devices have similar effectiveness, in other words, displaying a class effect across TAVI valves. We aimed to assess the comparative effectiveness of different TAVI platforms relative to other TAVI counterparts or surgical aortic valve replacement (SAVR).
Methods: MEDLINE/Embase/CENTRAL were searched from inception until April 2025, for randomized controlled trials comparing outcomes with different commercially available TAVI devices relative to other TAVI counterparts or SAVR.
Surg Infect (Larchmt)
September 2025
Department of Surgery, Division of Acute Care Surgery, University of Florida College of Medicine, Gainesville, Florida, USA.
Patients with traumatic injuries who develop ventilator-associated pneumonia (VAP) incur a higher risk of developing multi-drug resistance. Shorter duration of antibiotic agents for early VAP at five days may reduce antibiotic agent exposure without worsening patient outcomes. This retrospective cohort study performed at a Level I Trauma Center included adult (≥16 years old) patients with trauma diagnosed with bronchoalveolar lavage (BAL)-proven early (within four days of intubation) bacterial VAP.
View Article and Find Full Text PDFTurk Kardiyol Dern Ars
September 2025
Division of Arrhythmia and Electrophysiology, Department of Cardiology, University of Health Sciences, Yuksek Ihtisas Cardiovascular Building, Ankara City Hospital, Ankara, Türkiye.
Objective: Transvenous lead extraction (TLE) is used in various clinical scenarios, such as device-related infections. Mechanically powered sheaths are one of the most commonly used tools for TLE procedures. We evaluated the procedural and clinical outcomes of a novel extraction technique for chronically implanted leads in the treatment of device-related infections.
View Article and Find Full Text PDF